Brazil Medical Cannabis Market Size, Share, Trends, Forecast, Outlook Report, 2026-2034

Market Overview

The Brazil Medical Cannabis Market size was USD 856.53 Million in 2025 and is forecast to grow to USD 1,546.74 Million by 2034. The market is anticipated to expand at a CAGR of 6.79% during 2026-2034. Growth is driven by increasing therapeutic applications, advances in cultivation technologies, and digital integration that improve treatment efficiency and patient access.

Study Assumption Years

• Base Year: 2025

• Historical Years: 2020-2025

• Forecast Period: 2026-2034

Brazil Medical Cannabis Market Key Takeaways

• The Brazil medical cannabis market size was USD 856.53 Million in 2025.

• The market is projected to reach USD 1,546.74 Million by 2034.

• The market is expected to grow at a CAGR of 6.79% during 2026-2034.

• Growth is supported by expanding therapeutic uses of cannabis-based products treating chronic pain, neurological diseases, and palliative care.

• Technological advances in cultivation methods enhance product quality, consistency, and sustainability.

• Digital tools such as telemedicine and electronic prescriptions improve patient compliance and broaden access.

• Regulatory approvals, including recent authorization for industrial hemp cultivation, support market expansion.

Sample Request Link: https://www.imarcgroup.com/brazil-medical-cannabis-market/requestsample

Market Growth Factors

A growing number of physicians view cannabis-based medicines as potential therapeutic agents in the Brazil medical cannabis market and cannabis is used most often for chronic pain, neurological disorders, and palliative care. The medical evidence from new indications and other new uses from various active clinical trials has also led to increasing acceptance by doctors. In regard to cannabis as a medicine, the development of legal rulings such as the November 2024 Brazil Superior Court of Justice ruling approving industrial hemp cultivation, manufacture, sale, transport for medical purposes, is helping.

Cultivation techniques have greatly improved via controlled environment agriculture and precision irrigation to improve cannabinoid levels, improve product consistency, enable standardized quality parameters to be maintained, and reduce environmental degradation through improved resource use efficiency. Strain improvement for applied therapeutics has been undertaken based on research and market demand. Regulatory support for investment in modern facilities and secure supply chains promotes market growth.

Digital transformation in Brazil is expanding patient access to medical cannabis. Telemedicine platforms and electronic prescriptions ensure treatment adherence and monitoring for patients throughout Brazil, including in remote and under-served regions. Mobile applications for education and for symptom relief may increase patients' empowerment. The data that are submitted provide information about treatment outcomes to physicians and researchers, in the long run supporting personalized and evidence-based medicine. These technologies converge into a 'triple play' which increases safety, accessibility, and patient engagement to expand the market.

Market Segmentation

• Species Insights: Indica, Sativa, Hybrid

The report provides a detailed analysis based on species, categorizing the market into indica, sativa, and hybrid cannabis plants.

• Derivatives Insights: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others

The market is segmented by derivatives; cannabidiol (CBD), tetrahydrocannabinol (THC), and other cannabis derivatives are explored.

• Application Insights: Cancer, Arthritis, Migraine, Epilepsy, Others

Various medical applications are assessed, including cancer, arthritis, migraine, epilepsy, and other conditions.

• Route of Administration Insights: Oral Solutions and Capsules, Vaporizers, Topicals, Others

The market segments according to the administration route, including oral solutions and capsules, vaporizers, topicals, and others.

• End Use Insights: Pharmaceutical Industry, Research and Development Centres, Others

Analysis covers end-user segments such as the pharmaceutical industry, R&D centers, and other uses.

Regional Insights

The market is categorized regionally into Southeast, South, Northeast, North, and Central-West. While specific regional market shares or CAGR values are not explicitly quantified, these are the primary regions considered in the Brazilian market analysis. The report notes a growing and structured growth pattern supported by local regulation and investments across these regions.

Recent Developments & News

• In January 2025: MediPharm Labs Corp entered a commercial agreement with Laboratório Teuto, a leading Brazilian pharmaceutical manufacturer. ANVISA granted sanitary authorizations for two medical cannabis products from MediPharm, published in December 2024. This partnership allows Teuto to utilize its extensive distribution network in Brazil.

• In January 2024: Avicanna and Ease Labs Pharma received ANVISA approval to commercialize Brazil's first THC-containing pharmaceutical preparation, a GMP-certified product with 2.5% CBD and up to 0.2% THC, expected in pharmacies by March 2024.

Key Players

• MediPharm Labs Corp

• Laboratório Teuto

• Avicanna

• Ease Labs Pharma

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request Sample Customization:- https://www.imarcgroup.com/request?type=report&id=44121&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302